RNA Particle (RP) Technology Vaccine Platform for livestock (and pets)- a Timeline

"Prescription vaccines" for livestock, for any virus or bacteria, in 4 weeks. Coming soon to a human near you?

Today I went to add a livestock vaccine data point to the Edible Vaccine’s page at TotalityofEvidence, what should have been a simple task turned into a day long task of investigating, searching archive pages, and plotting timeline data points, and now writing up this substack.

If you are not already aware, the farm animals that make their way to our plate, (and potentially your pets) are already being injected with RNA Particle vaccine technology products. How extensive this is, I’ve not investigated. What this means to our health, that too I’ve not investigated. At this point it appears these products are definitely being used in pigs. It is unclear to me at this point if a Lipid NanoParticle is used to get the RNA into cells. It does appear that the RNA is being injected and not a protein.

Why has Merck Animal Health deleted all reference to their Sequivity RNA vaccine product?

Curiously, it was Vigilant Fox’s recent “sponsored” article that led me down this trail. I sometimes forget what links I have added to my pages, so I went to checked and discovered that Merck’s RNA swine vaccine (Sequivity) which they launched in 2018 has all the link broken, and being redirected to https://www.msd-animal-health.com/. Try it yourself HERE

I tried various domain formats and very few Sequivity pages are live. Maybe its a temporary glitch, but I find the timing curious to say the least.

Anyhow, moving on to discover how did we get to Merck’s RNA vaccine in the first place

This is how the timeline goes for RNA Particle vaccines:

2005

In 2005, while working as researchers at Iowa State University (ISU) in Ames, Iowa, two scientists Dr. D. L. (Hank) Harris, who was a professor in the Animal Science and Veterinary Diagnostic and Production Animal Medicine Departments and Dr. Matt Erdman (Postdoctoral Researcher at the time) discovered that two of the Porcine Reproductive and Respiratory Syndrome (PRRS) virus’ surface protein structures allowed the virus to 'cloak' itself from the pig's immune system.

These proteins were determined to be the Protective Antigenic Determinants (PAD) for the inducement of antibodies in pigs; thus making the proteins the target proteins for creating a vaccine.

“Iowa State University filed a provisional patent based on these findings in November of 2005, which has consequently been issued and exclusively licensed to Harrisvaccines.”¹ So the University Foundation will get patent royalties.

In 2005 , following this finding Dr Hank Harris sets up Sirrah, LLC or Sirrah-Bio, to develop swine vaccines, receiving initial funding from various agencies including the US Dept. of Ag. Sirrah-Bio will become Harrisvaccines Inc. around 2009² ³

During 2005, Erdman learned that scientists at a company called AlphaVax, a human vaccine company in North Carolina, had developed a replicon-based platform superior to conventional vaccine technology that was currently in use at the time. Based on other research, it appeared likely that AlphaVax’s replicon platform was a good match for delivering the Iowa State University PAD (viral protein elements) as a vaccine.

“AlphaVax uses a specialized viral vector system to make alphavirus replicon vaccines called alphavaccines”⁴

Thus, an alliance between the ISU and AlphaVax scientists was formed for collaborative research. In time, an evaluation agreement between AlphaVax and Harrisvaccines was signed. During the evaluation agreement, it was shown by Harrisvaccine scientists that a human vaccine prepared at AlphaVax for influenza would protect pigs against the influenza virus as well. This was the first time that the replicon technology had been used in pigs.

2007

In 2007, Harrisvaccines and AlphaVax signed an agreement for a field of use exclusive license for the replicon technology to be used in swine for vaccines for PRRS and Swine Influenza (SIV).⁵

March 2007 - “Sirrah completed its first round of financing and raised sufficient capital to hire employees and purchase equipment.  In July 2007, Sirrah will begin selling its unique Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) vaccines to select Iowa producers through its Veterinarian-Client-Patient (VCP) relationship.   … Sirrah will seek USDA approval to sell its PRRSV vaccine nationally, and internationally, in 2009.”

2009

Somewhere in 2009 Sirrah-Bio LLC transitioned to Harrisvaccines Inc, the latter website is only archived from 2009 - WEBSITE

It appears that Dr Matt Erdman has left the company by this time and has gone to work for the United States Department of Agriculture (USDA) according to his LinkedIn page. He is not on the Harrisvaccines board of directors in 2010.

In 2009 Harrisvaccines submits thier license application to the USDA for their new technology swine influenza virus (SIV), H3N2.

2010

Proof of concept paper is published January 2010 with the authors from both Harrisvaccines and Alphavax.

January 8, 2010 - Alphavirus replicon particle vaccines developed for use in humans induce high levels of antibodies to influenza virus hemagglutinin in swine: Proof of concept by Erdman, Harris (Harrisvaccines Inc) and Smith, Kamrud (Alphavax Inc) - READ

2011

On June 29, 2011 Merck announced a change of name for their animal health division from Intervet/Schering-Plough Animal Health to now Merck Animal Health⁶, and MSD Animal Health outside of USA and Canada. This is useful to know when you are looking at licensing documents, as I discovered.

2012

On September 20, 2012 Harrisvaccines announced that the United States Department of Agriculture (USDA) had granted them a license for the company's RNA Particle (RP) Platform technology swine flu vaccine, approved by the Department's Center for Veterinary Biologics (CVB) for disease caused by swine influenza virus (SIV) H3N2. This vaccine is the first to be licensed by the USDA CVB that utilizes RNA Particle Technology.

The Harrisvaccines employ their unique SirraVax^SM RNA Particle (RP) technology platform to develop rapid-response, herd-specific products for animal diseases. Once the platform gets approved (not the individual products) they will be able to make “prescription vaccines” at will. (Sirra is derived from the original company name).

The company also granted United States Veterinary Biologics Establishment License, #592, which approves their Iowa manufacturing facility to make new vaccines in the future, “for a broader spectrum of veterinary applications from swine and cattle to companion animal and farmed aquaculture."

At this time the Dr Erdman is working for the USDA in their inspection division!

RNA Particle vaccines now get pumped into swine, which then end up, unbeknownst to the public, on their dining table. It is still unclear if there is a Lipid NanoParticle used in this technology. Read the image below to find out how this SirraVax Platform works.

2013

By October 2013 “Harrisvaccines, Inc. Secures Exclusive Rights From AlphaVax, Inc. to Develop RNA Particle Vaccines for All Diseases in Companion Animals”⁷

Expect RNA vaccines to be rolled out to your pets, they likely are already.

2014

On June 17, 2014 Harrisvaccines’ Porcine Epidemic Diarrhea virus (PEDv) Vaccine is awarded a Conditional License⁸ which allows Harrisvaccines to sell the vaccine directly to veterinarians and swine producers. The vaccine had already sold “nearly 2 million doses through veterinary prescription already under a emergency use.

“The vaccine was introduced in August 2013 under the brand name iPED and quickly gained favor among veterinarians and pork producers. The newly licensed vaccine was renamed Porcine Epidemic Diarrhea Vaccine, RNA, which reflects its SirraVax RNA Particle Technology.”

In May 17, 2013 the first PED diagnosis in the United States occurred (conveniently) in Iowa. PED’s pathogenic agent is a coronavirus, which is distinguishable from transmissible gastroenteritis of swine (TGE) only by laboratory tests.⁹

Just days after the Spike gene sequence was confirmed from a “known Chinese strain of PDE” Harrisvaccines had a vaccine ready for production. [SERIOUSLY, does this sound familiar?]. iPED received conditional licence in 2013.¹⁰

source

2015

On September 21, 2015 the USDA Approves Harrisvaccines Avian Influenza Vaccine¹¹ in case of a poultry flu outbreak! As the SirraVax platform allows “researchers to adjust the drug to fight future strains”. Now vaccines are starting to be called “drugs”!

October 15, 2015 the US Government orders $6 million contracts for stockpile of Harrisvaccine’s Avian Flu Vaccine and another company.¹²

On November 12, 2015 Merck Animal Health announce they are acquiring Harrisvaccines Inc., just before the USDA approves the overarching new RNA Particle Technology Vaccine Platform.

2016

Big milestone for Merck

March 15, 2016 – Merck Animal Health Press Release: Harrisvaccines Receives Production Platform Vaccine Licensure First of its Kind Granted by USDA¹³

“Merck Animal Health today announced that its recent acquisition, Harrisvaccines, has been granted licensure of its Prescription Product, RNA Particle (RP) vaccine platform from the U.S. Department of Agriculture (USDA). This first-of-its-kind USDA license approves the company’s innovative production platform and allows for the manufacturing of herd-specific, custom vaccines prescribed by a licensed veterinarian.”

The vaccine platform and production process used is exactly the same for any disease. The only thing that differs is the gene [RNA sequence] inside the vaccine."

This appears to me to be Merck’s foot-in-the-door for human RNA “prescription”, personalised medicine, “vaccines”. What do you think?

2018

On June 6, 2018 Merck Animal Health announce their introduction of their SEQUIVITY™ Technology, which likely is the a REBRANDING of the SirraVax Platform. It is sold as an “innovative and highly advanced RNA Particle Technology is used to create flexible, safe and precise vaccine solutions to new and evolving disease challenges.”¹⁴

Merck released a 2 page summary whitepaper that summarises the “technology”. It is very hard at the moment to find any information on Sequivity.

source

“Millions of doses of the SEQUIVITY vaccine platform have safely been used by veterinarians in swine herds for more than ten years since the USDA first issued the license in 2012.”¹⁵ This is because they are quoting their acquisition of Harrisvaccines…it took me a few hours following leads to work this out.

On June 12, 2018 at the World Pork Expo, Merck Animal Health launched Sequivity. Have a listen to Joe Roder, DVM, technical services manager, Merck Animal Health. It is concerning that guess work seems to go into determining what gene sequence to use in the herd-specific vaccines!¹⁶

2021

Now fast forward to 2021, with the money for the sale of Harrisvaccines Inc to Merck AH and no doubt some kind of royalty kick-back, Dr Hank Harris and his son Joel Harris go on to co-founded Genvax Technologies, an animal-vaccine company. It doesn’t currently sell any vaccines, but has been working on an mRNA platform focused primarily on products for swine.¹⁷

“Because of all the advances on the human side for mRNA or mRNA-based vaccines we see this technology as the next step…”
Says Joel Harris

They will still be looking at “Custom & Herd-specific Vaccines”. I wonder what kickback’s Iowa University is still getting?

I see these animal products as a prelude to human products, but also who knows what this is doing to the animal products that we consume.

The timeline can also be found at TotalityofEvidence.com/edible-vaccines.

Please consider supporting my work…it is my income, and there is not much of that!

Sorry I am not a writer, if you are an avid reader, it is not my strength! I am a plotter of data points, capturing source links to history, before it disappears online or from our memories! I hope you find it useful in your education and helping to reveal the agenda “creep” to others.

1. https://web.archive.org/web/20100913053354/http://www.harrisvaccines.com/index.cfm?nodeID=18923

2. https://startsomething.cals.iastate.edu/people/hank-harris

3. https://www.linkedin.com/in/matt-erdman-3a64127

4. https://web.archive.org/web/20100925064608/http://www.alphavax.com/about/

5. https://web.archive.org/web/20100913053354/http://www.harrisvaccines.com/index.cfm?nodeID=18923

6. https://www.merck.com/news/merck-announces-new-name-for-its-animal-health-division/

7. https://www.prnewswire.com/news-releases/harrisvaccines-inc-secures-exclusive-rights-from-alphavax-inc-to-develop-rna-particle-vaccines-for-all-diseases-in-companion-animals-229679311.html

8. https://www.veterinarypracticenews.com/Harrisvaccines-PEDv-Vaccine-Wins-Conditional-License/

9. https://www.aphis.usda.gov/animal_health/animal_dis_spec/swine/downloads/ped_tech_note.pdf

10. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7117160/#bib0215

11. https://www.veterinarypracticenews.com/USDA-Approves-Avian-Influenza-Vaccine/

12. https://www.veterinarypracticenews.com/u-s-orders-stockpile-of-avian-flu-vaccine/

13. https://web.archive.org/web/20230412001452/https://www.merck-animal-health-usa.com/newsroom/harrisvaccines-receives-production-platform-vaccine-licensure-first-of-its-kind-granted-by-usda

14. https://www.merck-animal-health-usa.com/newsroom/merck-animal-health-introduces-sequivity-technology

15. https://web.archive.org/web/20230530033932if_/https://www.merck-animal-health.com/wp-content/uploads/2023/05/Merck-Sequivity-Statement.pdf

16. https://www.thepigsite.com/news/2018/06/merck-animal-health-introduces-sequivity-technology-1

17. https://agupdate.com/agriview/news/livestock/vaccines-target-swine-diseases/article_e268865f-9803-5f37-8905-381a4db2aef3.html